Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryHealth Care Equipment
SectorMedical
Phone224-667-6100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$30.58 billion
Profitability
Miscellaneous
Employees103,000
Next Earnings Date1/22/2020 (Estimated)
OptionableOptionable
Abbott Laboratories (NYSE:ABT) Frequently Asked Questions
What is Abbott Laboratories' stock symbol?
Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."
How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?
Abbott Laboratories announced a quarterly dividend on Thursday, September 12th. Shareholders of record on Tuesday, October 15th will be given a dividend of $0.32 per share on Friday, November 15th. This represents a $1.28 annualized dividend and a yield of 1.53%. The ex-dividend date of this dividend is Friday, October 11th. View Abbott Laboratories' Dividend History.
How were Abbott Laboratories' earnings last quarter?
Abbott Laboratories (NYSE:ABT) announced its quarterly earnings results on Wednesday, October, 16th. The healthcare product maker reported $0.84 earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of $0.84. The healthcare product maker had revenue of $8.08 billion for the quarter, compared to analysts' expectations of $8.10 billion. Abbott Laboratories had a return on equity of 17.65% and a net margin of 10.50%. Abbott Laboratories's revenue was up 5.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.75 earnings per share. View Abbott Laboratories' Earnings History.
When is Abbott Laboratories' next earnings date?
What guidance has Abbott Laboratories issued on next quarter's earnings?
Abbott Laboratories issued an update on its FY19 earnings guidance on Wednesday, October, 16th. The company provided EPS guidance of $3.23-3.25 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.24.
What price target have analysts set for ABT?
17 Wall Street analysts have issued 1 year target prices for Abbott Laboratories' shares. Their forecasts range from $68.00 to $98.00. On average, they anticipate Abbott Laboratories' share price to reach $87.22 in the next twelve months. This suggests a possible upside of 4.0% from the stock's current price. View Analyst Price Targets for Abbott Laboratories.
What is the consensus analysts' recommendation for Abbott Laboratories?
17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 2 sell ratings, 2 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Abbott Laboratories.
Has Abbott Laboratories been receiving favorable news coverage?
Media coverage about ABT stock has trended somewhat positive on Wednesday, according to InfoTrie. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Abbott Laboratories earned a daily sentiment score of 0.9 on InfoTrie's scale. They also assigned media headlines about the healthcare product maker a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Abbott Laboratories.
Are investors shorting Abbott Laboratories?
Abbott Laboratories saw a drop in short interest in the month of October. As of October 31st, there was short interest totalling 16,670,000 shares, a drop of 5.8% from the September 30th total of 17,690,000 shares. Based on an average daily volume of 4,520,000 shares, the days-to-cover ratio is currently 3.7 days. Approximately 1.0% of the company's stock are sold short. View Abbott Laboratories' Current Options Chain.
Who are some of Abbott Laboratories' key competitors?
Some companies that are related to Abbott Laboratories include Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Steris (STE), Hologic (HOLX), Varian Medical Systems (VAR) and Insulet (PODD).
What other stocks do shareholders of Abbott Laboratories own?
Who are Abbott Laboratories' key executives?
Abbott Laboratories' management team includes the folowing people:
- Mr. Miles D. White M.B.A., Chairman & CEO (Age 64)
- Mr. Robert B. Ford, Pres & COO (Age 45)
- Mr. Brian B. Yoor, Exec. VP of Fin. & CFO (Age 49)
- Mr. Hubert L. Allen, Exec. VP, Gen. Counsel & Sec. (Age 53)
- Mr. Stephen R. Fussell, Exec. VP of HR (Age 62)
Who are Abbott Laboratories' major shareholders?
Abbott Laboratories' stock is owned by many different of institutional and retail investors. Top institutional investors include Massachusetts Financial Services Co. MA (1.80%), Sumitomo Mitsui Trust Holdings Inc. (0.39%), Diamond Hill Capital Management Inc. (0.36%), California Public Employees Retirement System (0.23%), Rhumbline Advisers (0.19%) and Russell Investments Group Ltd. (0.15%). Company insiders that own Abbott Laboratories stock include Alejandro D Wellisch, Andrew H Lane, Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Daniel J Starks, Hubert L Allen, Jaime Contreras, Jared Watkin, John G Stratton, John M Capek, Joseph J Manning, Michael J Pederson, Miles D White, Randel William Woodgrift, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.
Which major investors are selling Abbott Laboratories stock?
ABT stock was sold by a variety of institutional investors in the last quarter, including Coho Partners Ltd., Massachusetts Financial Services Co. MA, Columbus Circle Investors, Sawgrass Asset Management LLC, Montag & Caldwell LLC, Sector Gamma AS, State of New Jersey Common Pension Fund D and BB&T Securities LLC. Company insiders that have sold Abbott Laboratories company stock in the last year include Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, John M Capek, Joseph J Manning, Michael J Pederson, Miles D White, Randel William Woodgrift, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.
Which major investors are buying Abbott Laboratories stock?
ABT stock was purchased by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Strs Ohio, Assenagon Asset Management S.A., State of Tennessee Treasury Department, Bartlett & Co. LLC, State of Alaska Department of Revenue, Banco Santander S.A. and First Trust Advisors LP. Company insiders that have bought Abbott Laboratories stock in the last two years include Daniel J Starks, John G Stratton and Randel William Woodgrift. View Insider Buying and Selling for Abbott Laboratories.
How do I buy shares of Abbott Laboratories?
Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Abbott Laboratories' stock price today?
One share of ABT stock can currently be purchased for approximately $83.89.
How big of a company is Abbott Laboratories?
Abbott Laboratories has a market capitalization of $148.36 billion and generates $30.58 billion in revenue each year. The healthcare product maker earns $2.37 billion in net income (profit) each year or $2.88 on an earnings per share basis. Abbott Laboratories employs 103,000 workers across the globe.View Additional Information About Abbott Laboratories.
What is Abbott Laboratories' official website?
How can I contact Abbott Laboratories?
Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.
MarketBeat Community Rating for Abbott Laboratories (NYSE ABT)
MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe ABT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABT will underperform the S&P 500 over the long term. You may vote once every thirty days.
